are glp- 1 makers being sued ⚠️ CHICAGO CONSUMER ALERT: The FDA has confirmed that counterfeit versions of popular GLP-1 weight-loss drugs—including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—are circulating in the U.S., and the Chicago area is GLP-1 RA Lawsuit - Shreveport

More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%). Lower-Burp Alternative Treatments For patients who cannot tolerate semaglutide due to persistent sulfur burps or other gastrointestinal side effects, alternative GLP-1 medications or weight loss medications may offer better tolerability

We are closely monitoring the pipeline to proactively share insights, clinical trials, and trend forecasting with you as they are released

The guarantee is conditional on timing

abrupt discontinuation Ongoing behavioral support Underlying metabolic factors Psychological factors Minimizing Weight Regain : Maintain strong nutrition and physical activity habits developed during treatment Consider gradual dose reduction rather than abrupt stopping Continue working with healthcare provider and coach during transition Monitor weight closely

Lebrun LJ, Lenaerts K, Kiers D, Pais de Barros JP, le Guern N, Plesnik J, Thomas C, Bourgeois T, Dejong CHC, Kox M, Hundscheid IHR, Khan NA, Mandard S, Deckert V, Pickkers P, Drucker DJ, Lagrost L, Grober J (2017) Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion

Poor sleep is associated with reduced GLP-1 response to meals, increased ghrelin (the hunger hormone), and impaired glucose tolerance